CURE’s gynecologic cancer page is an extensive resource of cancer information featuring the latest gynecologic cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on gynecologic cancer.
September 21st 2023
Rachelle’s unexpected departure reminded me I need to express my appreciation to these special, beloved providers now.
Phase 3 Trial to Study an Immunochemotherapy Regimen in Platinum-Resistant/Refractory Ovarian Cancer
September 26th 2022The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.
Cervical Cancer Survivor Donates Embryos to Fellow Survivor to Help Fulfill Dream of Motherhood
August 25th 2022Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.
Cancer Vaccine-Tecentriq Combo Elicits ‘Very Encouraging’ Outcomes in Advanced Cervical Cancer
May 10th 2022Treatment with an investigational cancer vaccine plus Tecentriq was associated with positive outcomes in patients with heavily pre-treated advanced cervical cancer, according to findings from an interim analysis of a phase 2 trial.
Imfinzi Fails to Improve Survival in Locally Advanced Cervical Cancer
March 25th 2022AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.
Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup
March 22nd 2022“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.
FDA Approves Second Keytruda Indication for Subset of Advanced Endometrial Cancer
March 21st 2022The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.